p75 neurotrophin receptor modulation in mild to moderate Alzheimer disease: a randomized, placebo-controlled phase 2a trial

Hayley R. C. Shanks,Kewei Chen,Eric M. Reiman,Kaj Blennow,Jeffrey L. Cummings,Stephen M. Massa,Frank M. Longo,Anne Börjesson-Hanson,Manfred Windisch,Taylor W. Schmitz

DOI: https://doi.org/10.1038/s41591-024-02977-w

IF: 82.9

2024-05-18

Nature Medicine

Abstract:p75 neurotrophin receptor (p75 NTR ) signaling pathways substantially overlap with degenerative networks active in Alzheimer disease (AD). Modulation of p75 NTR with the first-in-class small molecule LM11A-31 mitigates amyloid-induced and pathological tau-induced synaptic loss in preclinical models. Here we conducted a 26-week randomized, placebo-controlled, double-blinded phase 2a safety and exploratory endpoint trial of LM11A-31 in 242 participants with mild to moderate AD with three arms: placebo, 200 mg LM11A-31 and 400 mg LM11A-31, administered twice daily by oral capsules. This trial met its primary endpoint of safety and tolerability. Within the prespecified secondary and exploratory outcome domains (structural magnetic resonance imaging, fluorodeoxyglucose positron-emission tomography and cerebrospinal fluid biomarkers), significant drug–placebo differences were found, consistent with the hypothesis that LM11A-31 slows progression of pathophysiological features of AD; no significant effect of active treatment was observed on cognitive tests. Together, these results suggest that targeting p75 NTR with LM11A-31 warrants further investigation in larger-scale clinical trials of longer duration. EU Clinical Trials registration: 2015-005263-16; ClinicalTrials.gov registration: NCT03069014.

biochemistry & molecular biology,cell biology,medicine, research & experimental

What problem does this paper attempt to address?

The paper attempts to address the treatment of Alzheimer's disease (AD). Specifically, the researchers explored a novel small molecule drug, LM11A-31, which aims to slow the progression of the disease in patients with mild to moderate Alzheimer's by modulating the p75 neurotrophin receptor (p75NTR).

### Background
Alzheimer's disease is a complex and heterogeneous disorder characterized by synaptic dysfunction, degeneration, and loss due to multiple dysregulated mechanisms. Current primary treatments target the accumulation of β-amyloid (Aβ) or tau proteins, but these strategies only address narrow AD-related pathophysiological processes. Another strategy is to target "deep biology," which involves receptors and/or signaling networks that control multiple fundamental cellular pathways. This approach may normalize various AD-related pathological processes, particularly those related to synaptic plasticity and degeneration.

### Role of p75NTR
p75NTR is a member of the tumor necrosis factor family, traditionally considered a "death receptor." However, recent studies suggest it also determines the fate of synapses and cells. When unbound or bound to pro-neurotrophins like pro-NGF or pro-BDNF, p75NTR promotes degenerative signaling, leading to dendritic spine instability, synaptic degeneration, and neuronal death. Conversely, p75NTR can bind mature neurotrophins (such as NGF and BDNF) and act as a co-receptor with tyrosine receptor kinases (Trk), promoting cell survival and synaptic plasticity.

### Study Objective
This study aims to evaluate the safety and preliminary efficacy of LM11A-31, a small molecule based on the NGF β-hairpin loop 1 structure, which can downregulate p75NTR's degenerative signaling and act as an antagonist to pro-NGF-induced degeneration. The study is designed as a randomized, double-blind, placebo-controlled phase 2a clinical trial lasting 26 weeks, with three groups: placebo, 200 mg LM11A-31, and 400 mg LM11A-31, administered as oral capsules twice daily.

### Main Study Results
1. **Safety**: The study met its primary endpoint, demonstrating the safety and tolerability of LM11A-31.
2. **Biomarker Changes**:
- The longitudinal increase in CSF Aβ42 and Aβ40 was significantly slowed.
- The longitudinal increase in presynaptic SNAP25 and postsynaptic NG was significantly slowed.
- The longitudinal increase in YKL40 was significantly slowed.
3. **Cognitive Testing**: No significant effects of active treatment on cognitive tests were observed.

### Conclusion
The study results suggest that LM11A-31, by modulating p75NTR, has good safety and potential efficacy in patients with mild to moderate Alzheimer's disease. These findings warrant further investigation in larger and longer-term clinical trials.